<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The serine-threonine <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase kinase family member T-LAK cell-originated protein kinase (TOPK/PBK) is heavily involved in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> growth, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the identification of TOPK as a promising novel therapeutic target, no inhibitor of TOPK has yet been reported </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we screened 36 drug candidates using an in vitro kinase assay and identified the novel TOPK inhibitor HI-TOPK-032 </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro, HI-TOPK-032 strongly suppressed TOPK kinase activity but had little effect on extracellular signal-regulated kinase 1 (ERK1), c-jun-<z:chebi fb="0" ids="29318,29339">NH2</z:chebi>-kinase 1, or p38 kinase activities </plain></SENT>
<SENT sid="4" pm="."><plain>HI-TOPK-032 also inhibited anchorage-dependent and -independent <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell growth by reducing ERK-RSK phosphorylation as well as increasing <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> through regulation of the abundance of p53, cleaved caspase-7, and cleaved PARP </plain></SENT>
<SENT sid="5" pm="."><plain>In vivo, administration of HI-TOPK-032 suppressed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in a <z:hpo ids='HP_0003003'>colon cancer</z:hpo> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings therefore show that HI-TOPK-032 is a specific inhibitor of TOPK both in vitro and in vivo that may be further developed as a potential therapeutic against <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>